Updates from ASCO’s 2019 Annual Meeting
Each year , the American Society of Clinical Oncology (ASCO) brings together thousands of cancer experts to present and learn about recent breakthroughs in cancer research.
In this webinar, speaker Debu Tripathy, MD covers findings from MONALEESA-7, which showed premenopausal women who take a CDK 4/6 inhibitor as part of treatment for metastatic hormone receptor-positive breast cancer live longer than those who take hormonal therapy alone. He also discusses findings for people with all stages of disease and for those with HER2-positive and triple-negative breast cancer.
About Our SpeakerDebu Tripathy, MD is professor of medicine and chair of the department of breast medical oncology at the University of Texas MD Anderson Cancer Center. His clinical research focuses on the evaluation and development of new therapies in breast cancer, specifically growth factor receptor pathway targeting and biomarkers that predict sensitivity and resistance. Read more.